Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries
07:30am, Tuesday, 21'st Sep 2021
Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia
Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months
01:13pm, Friday, 17'th Sep 2021
You should want to know, because knowing when to put the gain in your wallet to be reinvested in the next one has very few better strategies.
Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021
07:30am, Wednesday, 15'th Sep 2021
-- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EXPAREL as of August 2021 --
Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08:00am, Wednesday, 08'th Sep 2021
PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:0
Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021
08:00am, Tuesday, 10'th Aug 2021
-- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 -- -- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 --
Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
12:13pm, Wednesday, 04'th Aug 2021
Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q2 2021 Results - Earnings Call Transcript
08:09pm, Tuesday, 03'rd Aug 2021
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q2 2021 Results - Earnings Call Transcript
Pacira (PCRX) Q2 Earnings Surpass Estimates
10:42am, Tuesday, 03'rd Aug 2021
Pacira (PCRX) delivered earnings and revenue surprises of 1.32% and -0.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021
08:00am, Tuesday, 03'rd Aug 2021
-- EXPAREL average daily sales at 178% of the prior year second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nas
Pacira (PCRX) Earnings Expected to Grow: Should You Buy?
04:05pm, Tuesday, 27'th Jul 2021
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021
07:30am, Tuesday, 20'th Jul 2021
PARSIPPANY, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets
Moving Average Crossover Alert: Pacira BioSciences (PCRX)
07:31am, Tuesday, 15'th Jun 2021
Pacira BioSciences (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021
08:00am, Tuesday, 08'th Jun 2021
-- EXPAREL average daily sales for May 2021 were 162% of May 2020 -- -- EXPAREL momentum continues with average daily sales for May 2021 at 105% of April 2021 --
Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries
09:23am, Wednesday, 26'th May 2021
Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal fossa) and saphenous (in adductor
Pacira BioSciences Looks To Reverse Current Trend, And A Huge Short Position Could Help
03:23pm, Tuesday, 11'th May 2021
Pacira BioSciences reported earnings last week, and the company missed on its EPS estimate while beating its revenue estimate.
